Menu
Back to Journals » Clinical, Cosmetic and Investigational Dermatology » Volume 12
Treatment Resistant Atopic Dermatitis: Challenges and Solutions [Corrigendum]
Authors Johnson BB , Franco AI, Beck LA, Prezzano JC
Received 6 December 2019
Accepted for publication 6 December 2019
Published 19 December 2019 Volume 2019:12 Pages 931—932
Johnson BB, Franco AI, Beck LA, Prezzano JC. Clin Cosmet Investig Dermatol. 2019; 12:181–192.
On page 189, Ustekinumab section, “Ustekinumab is a human monoclonal antibody that binds to the shared p40 protein subunit of human IL-12 and IL-23, thereby preventing interaction with their shared receptor.86 It is currently approved for Crohn’s disease, plaque psoriasis, and psoriatic arthritis. In a systematic review of ustekinumab in the treatment of AD including eight cases and two RCTs (n=107), a total of 58% of patients showed improvement in their AD.86 While ustekinumab was well tolerated, it is likely that it may only be effective for a subset of AD patients such as those with early-onset AD and possibly AD subjects of Asian descent.87,88” should read “Ustekinumab is a human monoclonal antibody that binds to the shared p40 protein subunit of human IL-12 and IL-23, thereby preventing interaction with their shared receptor.86 It is currently approved for Crohn’s disease, plaque psoriasis, and psoriatic arthritis. In a systematic review of ustekinumab in the treatment of AD including eight cases and two RCTs (n=107), a total of 54% of patients showed improvement in their AD (not clinically significant).86 While ustekinumab was well tolerated, it is likely that it may only be effective for a subset of AD patients such as those with early-onset AD and possibly AD subjects of Asian descent, though there is little current evidence to support its use.87,88”
Following feedback from a reader, we have clarified that the use of ustekinumab in the Pan et al study86 was not clinically significant. The authors apologize for this omission.
Read the original article
© 2019 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.